In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theragnostics Ltd.

http://theragnostics.com/

Latest From Theragnostics Ltd.

Lead From The Front – But Resist Micromanaging

Theragnostics’ CEO Greg Mullen aims to use his wide-ranging “hands-on” scientific and commercial experience to help clinch a $45m series A financing round that will fund a Phase I/II basket study to develop the biotech’s lead radiotherapeutic PARP inhibitor.

Business Strategies C-Suite Speaks

Device Financings: Recent Growth, Future Opportunities

A Reprint--see the article of the same name in In Vivo, May 2008.

Device Financings: Recent Growth, Future Opportunities

In Vivo analyzed recent public and private device financings to determine the comparative strengths and weaknesses of the various types of device financings, and further broke down the investments by therapeutic categories to examine what areas are hot and which ones are not. We found that the device industry has rebounded from a dismal public market and is showing strength among both public and private investors, resulting in a sector well-positioned for continued growth.

Medical Device

Deals Update (01/2008)

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Theragnostics, Inc.
UsernamePublicRestriction

Register